Accelerating Product Excellence in Innovation and for Clinical Adoption (APEx) (U24 Clinical Trial Not Allowed)

Federal funding opportunity RFA-DE-27-002 from National Institutes of Health (Department of Health and Human Services).

Posted: May 4, 2026
Closes: July 10, 2026
Award ceiling: $4,000,000
Program funding: $6,000,000
Cost sharing: No
Instrument: Cooperative Agreement
Assistance listing: 93.867, 93.121, 93.846
Category: Health
Archives: September 8, 2026

Program funding history

Awards made under Assistance Listing 93.867 across FY2024–FY2026, from public federal spending records.

FY2024 obligated: $689M
FY2025 obligated: $696.7M
FY2026 (to date) obligated: $332.4M
Awards in window: 3,337

Top recipients: The Johns Hopkins University, The Leland Stanford Junior University, Regents of the University of California, San Francisco, the, Jaeb Center for Health Research Foundation, Inc., Duke University

Source: USAspending.gov · refreshed July 2026

This opportunity is closed. Applications are no longer accepted. Similar open grants are listed below, and Grants Radar can alert you the next time funding like this posts.

Synopsis

This Notice of Funding Opportunity (NOFO) solicits cooperative agreement research applications to support a multidisciplinary program titled "Accelerating Product Excellence in Innovation and for Clinical Adoption" (APEx), that will facilitate advancement of promising strategies and products for tissue engineering and regenerative medicine (TE/RM). APEx will be composed of Resource Centers (RCs) and associated Interdisciplinary Translational Projects (ITPs) in the area of therapeutics (including adult stem cell-based treatments), sensors, and diagnostics. RCs will capitalize on their available clinical, scientific, industrial, regulatory and commercialization expertise, to deliver technical support, research capacity, administrative infrastructure and regulatory and commercialization support to the ITPs and guide them to complete pre-clinical studies toward initiation of clinical trials. During this funding cycle, APEx will complete validation, manufacturing, and preclinical testing of the most promising products, which may include, but are not limited to products for detecting or treating tissue damage caused by congenital defect, traumatic injury, or chronic disease. Products that support early detection of chronic pathologies, monitoring of validated biomarkers of health or disease, as well as approaches to reduce or prevent resulting damage, are especially encouraged. The outcome of APEx will be TE/RM products with their regulatory approvals in place for first-in-human studies, along with associated clinical study protocols, and synthesis and manufacturing protocols ready for initiation of clinical trials.

Who can apply

Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Public housing authorities/Indian housing authorities
Native American tribal governments (Federally recognized)
Public and State controlled institutions of higher education
For profit organizations other than small businesses
Private institutions of higher education
Small businesses
City or township governments
Independent school districts
Native American tribal organizations (other than Federally recognized tribal governments)
Special district governments
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
State governments
County governments

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/Foreign CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

How to apply

Applications go through the official government listing. Grants Radar links you straight to the source.

View on Grants.gov

Agency contact: National Institutes of Health · APEx-NOFO@nih.gov · 301-402-2541

Get grants like this every Tuesday — free

One email a week: the biggest new federal grants and what’s closing soon. Unsubscribe in one click.

The free edition carries one clearly labeled sponsor slot. No spam, ever. Privacy

Similar grants

Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)
PAR-25-274 · National Institutes of Health · closes November 17, 2026
Data Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative U24 Clinical Trial Required)
PAR-24-276 · National Institutes of Health · closes July 14, 2026
Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
PAR-25-268 · National Institutes of Health · closes November 17, 2026
Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science Award (CTSA) Program (R03 Clinical Trial Optional)
PAR-25-155 · National Institutes of Health · closes October 19, 2026
Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)
PAR-25-144 · National Institutes of Health · closes January 7, 2028
Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)
PAR-25-143 · National Institutes of Health · closes January 7, 2028

Never miss a funding deadline again

Grants Radar sends AI-enriched alerts on federal grants and contracts matched to what you do. Founding seats are limited and locked for life.

Get funding alerts